Erlotinib Not Yet Recruiting Phase 2 Trials for Biliary Tract Cancer Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03110484Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study